316 related articles for article (PubMed ID: 18058087)
1. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Arakawa R; Ito H; Takano A; Takahashi H; Morimoto T; Sassa T; Ohta K; Kato M; Okubo Y; Suhara T
Psychopharmacology (Berl); 2008 Apr; 197(2):229-35. PubMed ID: 18058087
[TBL] [Abstract][Full Text] [Related]
2. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
3. Striatal and extrastriatal dopamine D2 receptor occupancy by a novel antipsychotic, blonanserin: a PET study with [11C]raclopride and [11C]FLB 457 in schizophrenia.
Tateno A; Arakawa R; Okumura M; Fukuta H; Honjo K; Ishihara K; Nakamura H; Kumita S; Okubo Y
J Clin Psychopharmacol; 2013 Apr; 33(2):162-9. PubMed ID: 23422369
[TBL] [Abstract][Full Text] [Related]
4. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
[TBL] [Abstract][Full Text] [Related]
5. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone).
Vernaleken I; Fellows C; Janouschek H; Bröcheler A; Veselinovic T; Landvogt C; Boy C; Buchholz HG; Spreckelmeyer K; Bartenstein P; Cumming P; Hiemke C; Rösch F; Schäfer W; Wong DF; Gründer G
J Clin Psychopharmacol; 2008 Dec; 28(6):608-17. PubMed ID: 19011428
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Uchida H; Kapur S; Mulsant BH; Graff-Guerrero A; Pollock BG; Mamo DC
Am J Geriatr Psychiatry; 2009 Mar; 17(3):255-63. PubMed ID: 19225277
[TBL] [Abstract][Full Text] [Related]
7. Time course of dopamine D2 receptor occupancy by clozapine with medium and high plasma concentrations.
Takano A; Suhara T; Kusumi I; Takahashi Y; Asai Y; Yasuno F; Ichimiya T; Inoue M; Sudo Y; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):75-81. PubMed ID: 16040180
[TBL] [Abstract][Full Text] [Related]
8. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
[TBL] [Abstract][Full Text] [Related]
9. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
12. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Owen RT
Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.
Arakawa R; Ito H; Takano A; Okumura M; Takahashi H; Takano H; Okubo Y; Suhara T
Psychopharmacology (Berl); 2010 May; 209(4):285-90. PubMed ID: 20349050
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
[TBL] [Abstract][Full Text] [Related]
15. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
[TBL] [Abstract][Full Text] [Related]
16. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone.
Nyberg S; Farde L; Eriksson L; Halldin C; Eriksson B
Psychopharmacology (Berl); 1993; 110(3):265-72. PubMed ID: 7530376
[TBL] [Abstract][Full Text] [Related]
17. Error analysis for PET measurement of dopamine D2 receptor occupancy by antipsychotics with [11C]raclopride and [11C]FLB 457.
Ikoma Y; Ito H; Arakawa R; Okumura M; Seki C; Shidahara M; Takahashi H; Kimura Y; Kanno I; Suhara T
Neuroimage; 2008 Oct; 42(4):1285-94. PubMed ID: 18585466
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
19. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
20. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
